MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijid.2023.01.019

Медицинская библиотека · International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023

Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ).

Naggie Susanna, Milstone Aaron, Castro Mario, Collins Sean P, Lakshmi Seetha, Anderson Deverick J, Cahuayme-Zuniga Lizbeth, Turner Kisha Batey, Cohen Lauren W, Currier Judith, Fraulo Elizabeth, Friedland Anne, Garg Jyotsna, George Anoop, Mulder Hillary, Olson Rachel E, O'Brien Emily C, Rothman Russell L, Shenkman Elizabeth, Shostak Jack, Woods Christopher W, Anstrom Kevin J, Hernandez Adrian F, HERO Research Program

Рандомизированное исследованиеМногоцентровое исследованиеСтатьяEquivalence TrialПеревод в очереди

Аннотация

OBJECTIVES

To determine whether hydroxychloroquine (HCQ) is safe and effective at preventing COVID-19 infections among health care workers (HCWs).

METHODS

In a 1: 1 randomized, placebo-controlled, double-blind, parallel-group, superiority trial at 34 US clinical centers, 1360 HCWs at risk for COVID-19 infection were enrolled between April and November 2020. Participants were randomized to HCQ or matched placebo. The HCQ dosing included a loading dose of HCQ 600 mg twice on day 1, followed by 400 mg daily for 29 days. The primary outcome was a composite of confirmed or suspected COVID-19 clinical infection by day 30, defined as new-onset fever, cough, or dyspnea and either a positive SARS-CoV-2 polymerase chain reaction test (confirmed) or a lack of confirmatory testing due to local restrictions (suspected).

RESULTS

Study enrollment closed before full accrual due to recruitment challenges. The primary end point occurred in 41 (6.0%) participants receiving HCQ and 53 (7.8%) participants receiving placebo. No difference in the proportion of participants experiencing clinical infection (estimated difference of -1.8%, 95% confidence interval -4.6-0.9%, P = 0.20) was identified nor any significant safety issues.

CONCLUSION

Oral HCQ taken as prescribed appeared safe among HCWs. No significant clinical benefits were observed. The study was not powered to detect a small but potentially important reduction in infection.

TRIAL REGISTRATION: NCT04334148.

Для цитирования: Naggie Susanna, Milstone Aaron, Castro Mario, Collins Sean P, Lakshmi Seetha, Anderson Deverick J, Cahuayme-Zuniga Lizbeth, Turner Kisha Batey, Cohen Lauren W, Currier Judith, Fraulo Elizabeth, Friedland Anne, Garg Jyotsna, George Anoop, Mulder Hillary, Olson Rachel E, O'Brien Emily C, Rothman Russell L, Shenkman Elizabeth, Shostak Jack, Woods Christopher W, Anstrom Kevin J, Hernandez Adrian F, HERO Research Program. Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ).. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2023. DOI: 10.1016/j.ijid.2023.01.019.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.